Role of the Serine-Rich Surface Glycoprotein Srr1 of Streptococcus agalactiae in the Pathogenesis of Infective Endocarditis

Ho Seong Seo¹, Yan Q. Xiong²,³, Paul M. Sullam¹*

¹ Division of Infectious Diseases, Veterans Affairs Medical Center and the University of California San Francisco, San Francisco, California, United States of America, ² Department of Medicine, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, California, United States of America, ³ Geffen School of Medicine at UCLA, Los Angeles, California, United States of America

Abstract

The binding of bacteria to fibrinogen and platelets are important events in the pathogenesis of infective endocarditis. Srr1 is a serine-rich repeat glycoprotein of Streptococcus agalactiae that binds directly to the Aα chain of human fibrinogen. To assess the impact of Srr1 on the pathogenesis of endocarditis due to S. agalactiae, we first examined the binding of this organism to immobilized human platelets. Strains expressing Srr1 had significantly higher levels of binding to human platelets in vitro, as compared with isogenic Δsrr1 mutants. In addition, platelet binding was inhibited by pretreatment with anti-fibrinogen IgG or purified Srr1 binding region. To assess the contribution of Srr1 to pathogenicity, we compared the relative virulence of S. agalactiae NCTC 10/84 strain and its Δsrr1 mutant in a rat model of endocarditis, where animals were co-infected with the WT and the mutant strains at a 1:1 ratio. At 72 h post-infection, bacterial densities (CFU/g) of the WT strain within vegetations, kidneys, and spleens were significantly higher, as compared with the Δsrr1 mutant. These results indicate that Srr1 contributes to the pathogenesis of endocarditis due to S. agalactiae, at least in part through its role in fibrinogen-mediated platelet binding.

Introduction

Streptococcus agalactiae (Group B streptococcus [GBS]) is a frequent cause of neonatal meningitis and sepsis. In recent years, however, GBS infections in nonpregnant adults are being increasingly reported. Individuals at greater risk for this disease include the elderly, immunosuppressed patients, and diabetics [1–3]. Although GBS is a relatively uncommon cause of endocarditis (accounting for 1–2% of culture-positive cases), endovascular infection due to this organism is associated with a high mortality rate (34–50%), especially in the setting of prosthetic valve infection [4–7]. Complications such as sepsis, valvular destruction, cardiac failure, and embolic phenomena are also frequent in this disease [8].

The pathogenesis of endocarditis is a complex process, involving multiple host-pathogen interactions. A central aspect of virulence in this disease is the ability of organisms to bind host components, such as fibrinogen, fibronectin, and platelets [9–13]. These binding events appear to be important both for the initial attachment of bacteria to the endovascular surface, and for the subsequent progression of infection. For several Gram-positive bacteria, binding to human platelets is mediated in part by an adhesin belonging to the serine-rich repeat (SRR) glycoprotein [14–16]. For example, strains of Streptococcus gordonii can bind platelets directly via the interaction of the SRR adhesins GspB or Hsa with a receptor (GPIb) on the platelet membrane [15]. The binding of Staphylococcus aureus to platelets is mediated in part by the SRR protein SraP, though the receptor for this adhesin remains unidentified [17]. In addition, S. aureus can attach to platelets via fibrinogen and fibrin, which act as a molecular bridge between the bacteria and platelet surface [18–20].

Two SRR glycoproteins (Srr1 and Srr2) have been identified thus far in S. agalactiae [21]. Expression of Srr1 has been shown to contribute to colonization and virulence in models of GBS bacteremia and meningitis infection [22–25]. In addition, we have recently demonstrated that Srr1 binds to human fibrinogen via its interaction with the Aα chain of the protein, and that loss of fibrinogen binding is associated with decreased attachment to brain microvascular endothelial cells in vitro, as well as attenuated virulence, in an experimental model of meningitis [26]. In view of the importance of fibrinogen binding for endovascular infection, we examined the impact of Srr1 on platelet binding in vitro, and its role in the pathogenesis of infective endocarditis.

Materials and Methods

Reagents

Purified human fibrinogen was obtained from Haematologic Technologies. Rat fibrinogen was purchased from Sigma-Aldrich.
Rabbit anti-fibrinogen IgG was acquired from Innovative Research.

Strains, plasmids, and growth conditions

The bacteria and plasmids used in this study are listed in Tables 1. *Streptococcus agalactiae* strains were grown in Todd-Hewitt broth (Difco) supplemented with 0.5% yeast extract (THY broth). All mutant strains grew at a comparable rate *in vitro* as compared with respective parental strains (data not shown). *Escherichia coli* strains DH5α, BL21 and BL21(DE3) were grown at 37°C under aeration in Luria Bertani broth (LB; Difco). Antibiotics were added to the media as required. All isolates were stored at -80°C until thawed just prior to use.

Cloning and expression of the Srr1 binding region (Srr1-BR)

Genomic DNA was isolated from GBS NCTC 10/84 using Wizard Genomic DNA purification kits (Promega), according to the manufacturer’s instructions. PCR products were cloned into either pET28FLAG or pET22(+) to express FLAG-tagged or His6-tagged versions of Srr1-BR (amino acids [AA] 303–641 of the SRR1). Proteins were purified by either Ni-NTA (Promega) or His6-monoclonal antibody. For some studies, the wells were preinoculated with His6-tagged Srr1-BR (0–50 μM) or anti-fibrinogen IgG (0–100 μg/ml) for 0.5 h at RT followed by washing, prior to adding FLA(Srr1-BR) (1 μM).

Binding of recombinant Srr1-BR to human platelets

Fixed human platelets were immobilized in 96 well cell culture plates as described previously [28]. After treatment with a casein-based blocking reagent, the wells were incubated with FLA(Srr1-BR) (0–4 μM) in PBS for 1 h at room temperature, followed by washing. Bound protein was detected by ELISA with anti-FLAG monoclonal antibody. For some studies, the wells were preincubated with His6-tagged Srr1-BR (0–50 μM) or anti-fibrinogen IgG (0–100 μg/ml) for 0.5 h at RT followed by washing, prior to adding FLA(Srr1-BR) (1 μM).

Rat model of infective endocarditis

The relative virulence of *S. agalactiae* NCTC 10/84 parental strain and its isogenic variant (NCTC 10/84 Δsrr1) was assessed in a competition model of IE in rats, as described previously [29,30]. In brief, Sprague-Dawley female rats (250 to 300 g, Harlan Laboratory, Inc.) were first anesthetized with ketamine (35 mg/kg) and xylazine (10 mg/kg). A sterile polyethylene catheter was surgically placed across the aortic valve of each animal, such that the tip was positioned in the left ventricle, to induce the formation of sterile valvular vegetations (nonbacterial thrombotic endocarditis) [27,29]. The catheters were left in place throughout the study. Three days post-catheterization, the animals were infected intravenously with an inoculum of approximately 5×10⁸ CFU containing a 1:1 mixture of *S. agalactiae* NCTC 10/84 and its Δsrr1 isogenic variant. At 72 hr post-infection, the rats were euthanized with thiopental (10 mg IP). Animals were included in the final analysis only if the catheters were correctly positioned across the aortic valve at the time of sacrifice, and if macroscopic vegetations were visible. At sacrifice, all cardiac vegetations, as well as kidneys and spleens, were harvested, weighed, homogenized in saline, with PBS to remove nonadherent organisms. The wells were treated with 100 μl of trypsin (2.5 mg/ml) for 10 min at 37°C to release the attached bacteria, and the number of bound bacteria was determined by plating serial dilutions of the recovered bacteria onto blood agar plates as previously described [27].

Table 1. Strains and plasmids.

| Strains                                                                 | Genotype or description* | Source               |
|------------------------------------------------------------------------|--------------------------|----------------------|
| *Escherichia coli*                                                     |                          |                      |
| DH5α                                                                  | F' r m*O80dlocZAM15      | Gibco BRL            |
| BL21 (DE3)                                                            | expression host, inducible T7 RNA polymerase | Novagen             |
| Streptococcus agalactiae                                               |                          |                      |
| COH31                                                                 | serotype III, clinical isolate | [51]               |
| PS2645                                                                | NCTC 10/84               | [23]               |
| PS2645                                                                | NCTC 10/84Δsrr1, CmR     | this study           |
| NCTC 10/84Δsrr1, CmR                                                  |                          |                      |
| Plasmids                                                              | Description*             | Source               |
| pDE123                                                                | streptococcal shuttle vector, EmR | [26]               |
| pDE123Δ-srr1                                                          | vector for expression of Srr1, EmR | [26]               |
| pET22b(+)                                                             | expression vector, AmpR  | Novagen             |
| pET28FLAG                                                             | vector with FLAG-tag, KanR | [27]                |
| pET22-Srr1-BR                                                         | vector for expression of Srr1-1, AmpR | [26]               |
| pET28FLAG-Srr1-1, AmpR                                                 | vector for expression of FLAG-tagged Srr1203–641 | this study          |

*CMR, chloramphenicol resistance; EmR, erythromycin resistance; AmpR, ampicillin resistance; KanR, kanamycin resistance.

doi:10.1371/journal.pone.0064204.t001
serially diluted, and plated onto 8% sheep blood Todd Hewitt agar (with or without 2.5 μg/ml of chloramphenicol) for quantitative culture. The plates were incubated for 48 h at 37°C, and bacterial densities were expressed as the log_{10}CFU per gram of tissue. Differences in means +/− SD were compared for statistical significance by the paired t-test. The data were also analyzed by calculating a "competition index," which was defined as the ratio of the paired strains within tissues for each animal, normalized by the ratio of organisms in the inoculum [27,29]. The mean of the log_{10} normalized ratios was tested against the hypothesized 'no effect' mean value of 0, using a paired t-test, with $P_{\leq}0.05$ as the threshold for statistical significance.

Animals were maintained in accordance with the American Association for Accreditation of Laboratory Animal Care (AAALAC) criteria. All animal studies were approved by the Animal Research Committee (IACUC) of the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center.

Statistical methods

Data expressed as means ± standard deviations were compared for statistical significance by the paired or unpaired *t*-test, as indicated.

**Results**

**Binding of GBS to human platelets is mediated by fibrinogen**

To assess whether GBS binding to human platelets is mediated by Srr1, we compared two GBS strains (COH31 and NCTC 10/84) and their respective Δsrr1 isogenic variants, and the mutant strains complemented in trans with srr1 (pSrr1). Both strains bound platelets significantly above background levels, with 28.0 ± 2.6% and 12.0 ± 2.6% (mean ± SD) of the inoculum bound for COH31 and NCTC 10/84, respectively. Levels of binding by both srr1 mutant strains were significantly lower than those of the parent strains, with a 79.2 ± 3.4% reduction in platelet binding for COH31Δsrr1 and a 71.4 ± 4.2% reduction for NCTC 10/84Δsrr1.

Figure 1. GBS binding to immobilized human platelets is mediated by glycoprotein Srr1. (A) Platelet binding by GBS strains COH31 and NCTC 10/84, their Δsrr1 isogenic variants, and the mutant strains complemented in trans with srr1 (pSrr1). (B) GBS binding to human platelets was inhibited by pretreating the monolayers with 100 μg/ml of anti-fibrinogen IgG (Anti-Fg). Normal IgG (IgG) served as a control. (C) Inhibition of binding by recombinant Srr1 binding region (Srr1-BR). Levels of binding were calculated as relative to the WT strains (mean ± SD). Values shown represent the means (± S.D.) of triplicate measurements. * = $P_{\leq}0.01$.

doi:10.1371/journal.pone.0064204.g001

Figure 2. Recombinant Srr1-BR interacts with human platelets. (A) Binding of FLAG::Srr1-BR protein to immobilized platelets. (B) Inhibition of FLAG::Srr1-BR binding to platelets by His6 tagged Srr1-BR. Platelets were pretreated with the indicated concentrations of His6 tagged Srr1-BR. (C) Binding of FLAG::Srr1-BR to immobilized platelets pretreated with anti-fibrinogen IgG or preimmune rabbit IgG. Values represent relative binding of FLAG::Srr1-BR binding as compared with untreated platelets. Bars indicate the means (± S.D.). * = $P_{\leq}0.01$.

doi:10.1371/journal.pone.0064204.g002
Complementation of the srr1 mutation in trans restored binding by both mutant strains, thereby demonstrating that the loss of binding observed with srr1 disruption was not due to polar or pleiotropic effects. In addition, GBS binding to human platelets was inhibited by rabbit anti-fibrinogen IgG, but not by normal rabbit IgG (Fig. 1B), with WT GBS binding levels reduced to those seen with the srr1 deletion strains. We then examined the impact of preincubating the platelet monolayers with the recombinant binding domain of Srr1 (Srr1-BR). As shown in Fig. 1C, pretreating the immobilized platelets with recombinant Srr1-BR inhibited subsequent binding by both GBS strains. Since previous studies have shown that human platelets express membrane-associated fibrinogen [11,31,32], our results indicate that GBS binding to human platelets is mediated by the interaction of Srr1 with fibrinogen on the surface of these cells.

**Binding of Srr1-BR to immobilized platelets**

To further assess the role of Srr1, we evaluated the binding of FLAG-tagged Srr1-BR (FLAGSrr1-BR) to immobilized human platelets. We found that FLAGSrr1-BR interacted with platelets in a concentration-dependent manner, when tested over a range of 0–4 μM (Fig. 2A). In addition, binding was significantly inhibited by preincubating the platelets with His6-tagged Srr1-BR, (Fig. 2B) or anti-fibrinogen IgG (Fig. 2C). These results demonstrate that Srr1-BR can bind platelets via its interaction with fibrinogen, and that this interaction is specific.

**Effect of Srr1 expression on streptococcal endocarditis**

Some fibrinogen binding proteins, such as ClfA of S. aureus, bind fibrinogen from only certain animal species [33]. With a view towards in vivo studies, we next sought to assess whether Srr1 had a similar impact on the interaction of GBS with rat fibrinogen. PSI-BLAST analysis indicated that the predicted binding region in rat fibrinogen is located at AA294–334 of the Aα chain, which has 49% identity with the Srr1 binding site on human fibrinogen (Fig. 3A). When tested in vitro, binding of the isogenic mutants to rat fibrinogen was found to be significantly lower than that of wild type strains COH31 and NCTC 10/84 (Fig. 3B). In addition, FLAGSrr1-BR was bound to immobilized rat fibrinogen in a concentration-dependent manner, as was seen previously with human fibrinogen (Fig. 3C) [26].

To examine the impact of Srr1 expression on the pathogenesis of endocarditis, we compared the relative virulence of GBS NCTC 10/84 with its isogenic mutant (Δsrr1), as measured by a rat co-infection model of this disease. Animals (n = 14) had significantly lower densities of the mutant strain (mean log 10 CFU/g 6 SD = 7.46 ± 1.63) within vegetations as compared with the parent strain (8.62 ± 1.25). Levels of the mutant strain were also significantly reduced within kidneys and spleens (Table 2). We then re-analyzed these data by comparing the ratio of the isogenic strains within tissues, with the CFU of each strain normalized to the number of CFU within the inoculum (competition index) (Fig. 4). When assessed by this approach, the levels of the srr1 mutant (Δsrr1) remained significantly reduced in all tissues, as compared with WT. Thus, Srr1 appears to be a significant virulence determinant for the pathogenesis of endocarditis due to GBS.

---

**Table 2. Impact of Srr1 on virulence in an animal model of endocarditis.**

| Vegetations | Mean ± S.D. (log10 CFU/g) | p value | Kidneys | Mean ± S.D. (log10 CFU/g) | p value | Spleens | Mean ± S.D. (log10 CFU/g) | p value |
|-------------|--------------------------|---------|---------|--------------------------|---------|---------|--------------------------|---------|
| NCTC 10/84  | 8.62±1.25                | 0.014   | 6.85±0.73 | 0.006                    | 6.51±0.89 | 0.029   |
| Δsrr1       | 7.46±1.63                |         | 6.08±0.86 |             |         | 5.96±0.80 |

Infective endocarditis was induced in rats, using an inoculum of 5 × 10⁸ CFU containing GBS NCTC10/84 and its isogenic Δsrr1 mutant, at a 1:1 ratio. Animals were sacrificed 72 h post-infection, and log10 CFU/g of tissue for each strain was determined by plating onto selective media.

---

doi:10.1371/journal.pone.0064204.g003

doi:10.1371/journal.pone.0064204.t002
Figure 4. Competitive index (CI) analysis of WT and Δsrr1 mutant obtained in the rat model of endocarditis. Competition index (CI) was calculated as the ratio of the WT to the Δsrr1 mutant in each tissue, normalized for the ratio of strains within the inoculum. Circles represent data from individual animals. A CI above 10² (dashed line) indicates a competitive disadvantage of Δsrr1 compared with WT. Horizontal black bars indicate means of CIs.

Discussion

A number of bacterial surface structures have been shown to mediate binding to fibrinogen, such as ClfA, ClfB, FabA and FbsB of S. aureus, and the Fss proteins of Enterococcus faecalis [33–38]. We recently identified Sr1 of GBS as a fibrinogen-binding protein that was important for bacterial attachment to microvascular endothelial cells and CNS invasion [26]. Although the binding region of Sr1 has limited homology to other adhesins, analysis of its predicted secondary structure indicated that the conformation of this domain would resemble the binding region of ClfB. As has been shown for several other adhesins, the binding pocket of ClfB is formed by two Ig folds that engage the Aα chain of fibrinogen via a “dock, lock, and latch” mechanism [35,39]. Sr1 appears to interact with fibrinogen Aα by a similar mechanism, since deletion of the predicted latch region abrogates fibrinogen binding by the protein, and markedly reduces virulence in an animal model of meningitis [26].

Our results indicate that Sr1-mediated binding to fibrinogen also contributes to the pathogenesis of infective endocarditis. Reduced fibrinogen binding in vitro was associated with decreased virulence, as measured by our co-infection (competition) model of endovascular infection. In particular, densities (CFU/g) of an Sr1 deletion mutant were significantly lower, as compared with its parent strain, both within vegetations and in kidneys and spleens. Of note, the mutant strain was not entirely avirulent, as it still expresses other factors that contribute to its virulence, and is consistent with other studies on the role of microbial binding in endocarditis, where mutation or deletion of a single adhesin produces only a partial reduction in pathogenicity [17,29,30]. GBS are known to express other fibrinogen binding proteins (FbsA and FbsB), which may have contributed to the residual virulence of our Δsrr1 mutant strain [37,38]. Moreover it is likely that GBS express additional surface components that can mediate binding to cardiac valves, or enhance virulence by other mechanisms.

Binding to fibrinogen may be important for a number of events in the pathogenesis of endovascular infections [10,40,41]. First, bacterial attachment to the endocardium generally requires prior alteration of the valve surface, such that it is covered with a matrix of platelets and host proteins, including fibrinogen [20,42–45]. Studies with S. aureus have shown that fibrinogen immobilized on the valve surface is likely to contribute to the attachment of circulating bacteria, thereby initiating infection [46–50]. Our current results indicate that fibrinogen may have a similar role for GBS. In addition, fibrinogen in plasma could also serve to crosslink GBS to platelets that have aggregated at sites of valve injury. The subsequent progression of endovascular infection may also be enhanced by GBS binding to fibrinogen. Bacteria proliferating on the valve surface bacteria are thought to induce the further deposition of fibrinogen onto the infected valve, which in turn, is likely to trigger platelet attachment and aggregation. These processes, in combination with bacterial growth, result in the production of vegetations [9,10]. In view of our in vitro studies, where Sr1-1 enhanced the binding of bacteria to both fibrinogen and platelets, it is possible that Sr1-fibrinogen binding may be one mechanism for the continued recruitment of platelets in vivo to the infected endocardium, thereby stimulating disease progression.

A longstanding therapeutic goal has been to develop agents that block bacterial binding to host tissues, thereby preventing or attenuating subsequent infection. Fibrinogen binding is an appealing target for disruption, in view of the importance of this interaction for the pathogenesis of infective endocarditis. Although inhibitory agents could target specific adhesins individually, such as Sr1, an alternative strategy might be to develop drugs that interfere with a larger number of “dock, lock, and latch” adhesins. Although the binding clefts of these adhesins vary in terms of their primary amino acid sequence, it may still be possible to generate agents that block binding, either by preventing docking, or by inhibiting the latching process. If successful, this approach would yield an inhibitor that could be used for a variety of pathogens.

Acknowledgments

We thank Dr. Barbara Bensing and Dr. Arnold S. Bayer for their helpful scientific and editorial advice, and Dr. Kelly Doran for providing the GBS isolates used in these studies.

Author Contributions

Conceived and designed the experiments: HSS YQX PMS. Performed the experiments: HSS YQX. Analyzed the data: HSS YQX PMS. Contributed reagents/materials/analysis tools: HSS YQX PMS. Wrote the paper: HSS YQX PMS.

References

1. Sunkara B, Bheemreddy S, Loebber B, Lephart PR, Hayakawa K, et al. (2012) Group B Streptococcus infections in non-pregnant adults: the role of immunosuppression. Int J Infect Dis 16: e182–186.
2. Farley MM (2001) Group B streptococcal disease in nonpregnant adults. Clin Infect Dis 33: 536–561.
3. Munoz P, Llanasquero A, Rodriguez-Creixems M, Pelaez T, Martin L, et al. (1997) Group B streptococcus bacteremia in nonpregnant adults. Arch Intern Med 157: 213–216.
4. Siciliano RF, Cas D, Navarro RC, Strabelli TM (2010) Acute Staphylococcus agalactiae endocarditis: outcomes of early surgical treatment. Heart Lung 39: 331–334.
5. Ivanova Georgieva R, Garcia Lopez MV, Ruiz-Morales J, Martinez-Marcos IJ, Lomas JM, et al. (2010) Staphylococcus agalactiae left-sided infective endocarditis. Analysis of 27 cases from a multicentric cohort. J Infect 61: 34–39.
6. Rollan MJ, San Roman JA, Villacosta I, Sarría C, Lopez J, et al. (2003) Clinical profile of Staphylococcus agalactiae native valve endocarditis. Am Heart J 146: 1095–1098.
7. Sanholu A, Miro JM, Tornos MP, Almirante B, Moreno-Torrico A, et al. (2002) Staphylococcus agalactiae infective endocarditis: analysis of 30 cases and review of the literature. 1962-1998. Clin Infect Dis 34: 1576–1584.
8. Kannan R, Komarnathch AM, Mathew T, Ramprakash B, Sundaramaraman T, et al. (2001) Staphylococcus agalactiae endocarditis. J Assoc Physicians India 49: 1125–1126.
9. Fitzgerald JR, Loughman A, Keane F, Brennan M, Knobel M, et al. (2006) Fibronectin-binding proteins of \textit{Streptococcus agalactiae} mediate activation of human platelets via fibronogen and fibronectin bridges to integrin GPIb-IIIa and IgG binding to the FcgammaRIIa receptor. Mol Microbiol 59: 212–230.

10. Loughman A, Fitzgerald JR, Brennan MP, Higgs J, Downer R, et al. (2005) Roles for fibronogen, immunoglobulin and complement in platelet activation promoted by \textit{Streptococcus agalactiae} clumping factor A. Mol Microbiol 57: 810–818.

11. Fitzgerald JR, Foster TJ, Cox D (2006) The interaction of bacterial pathogens with platelets. Nat Rev Microbiol 4: 445–457.

12. Moreillon P, Que YA, Bayer AS (2002) Pathogenesis of streptococcal and staphylococcal endocarditis. Infect Dis Clin North Am 16: 297–318.

13. Veloso TR, Chaouch A, Roger T, Giddey M, Vouillamoz J, et al. (2012) Use of a human-like low-grade bacteremia model of experimental endocarditis to study the role of \textit{Streptococcus gordonii} adhesins and platelet aggregation in early endocarditis. Infect Immun 81(5): 697–703.

14. Zhou M, Wu H (2009) Glycosylation and biogenesis of a family of serine-rich bacterial adhesins. Microbiology 155: 317–327.

15. Bensing BA, Lopez JA, Sullam PM (2004) The \textit{Streptococcus gordonii} surface proteins GspB and Hsa mediate binding to sialylated carbohydrate epitopes on the platelet membrane glycoprotein Ibalpha. Infect Immun 72: 6526–6537.

16. Lucano A, Sanchez CJ, Ozhukha CJ (2012) A role for glycosylated serine-rich repeat proteins in gram-positive bacterial pathogenesis. Mol Oral Microbiol 27: 257–269.

17. Siboo IR, Chambers HF, Sullam PM (2005) Role of SraP, a Serine-Rich Surface Protein of \textit{Staphylococcus aureus}, in binding to human platelets. Infect Immun 73: 2273–2280.

18. Heilmann C, Niemann S, Sinha B, Herrmann M, Kehrel BE, et al. (2004) \textit{Streptococcus gordonii} fibronectin-binding protein (FnBP)-mediated adhesion to platelets, and aggregation of platelets induced by FnBP but not by FlnBP. J Infect Dis 190: 321–329.

19. Majdicov H, Loughman A, Brennan M, Cox D, Foster TJ (2007) Both complement- and fibronogen-dependent mechanisms contribute to platelet aggregation mediated by \textit{Streptococcus agalactiae} clumping factor C. Infect Immun 75: 3335–3343.

20. Pietrocola G, Schubert A, Visai L, Torti M, Fitzgerald JR, et al. (2005) FbsA, a fibronectin-binding protein from \textit{Staphylococcus agalactiae}, mediates platelet aggregation. Blood 105: 1052–1059.

21. Tazi A, Bellais S, Tardieux I, Dramsi S, Trieu-Cuot P, et al. (2012) Group B \textit{Streptococcus} and \textit{Staphylococcus} adhesins and platelet aggregation mediated by \textit{Staphylococcus aureus} clumping factor B/ligand interactions. J Biol Chem 287: 25963–25972.

22. Siboo IR, Chambers HF, Sullam PM (2005) Role of SraP, a Serine-Rich Surface Protein of \textit{Staphylococcus aureus}, in binding to human platelets. Infect Immun 73: 2273–2280.

23. van Sorge NM, Quach D, Gurney MA, Sullam PM, Nizet V, et al. (2009) The \textit{Streptococcus mitis} fibrinogen-binding protein, EfB, from \textit{Streptococcus agalactiae} binds to platelets and inhibits platelet aggregation. Thromb Haemost 97: 779–789.

24. Ganea VB, Barba EM, Daianazagam CC, Le B, Anderson AS, et al. (2011) Structural and biochemical characterization of \textit{Staphylococcus aureus} clumping factor B, ligand interactions. J Biol Chem 286: 23963–23972.

25. Seo HS, Sullam PM (2011) Characterization of the fibrinogen binding domain of \textit{Streptococcus mitis} fibrinogen-binding protein. PLoS Pathog 7: e1002118.

26. Mitchell J, Siboo IR, Takamatsu D, Chambers HF, Sullam PM (2007) Mechanism of cell surface expression of the \textit{Streptococcus mitis} platelet binding protein PhaA and Phb. Mol Microbiol 64: 844–857.

27. Mitchell J, Sullam PM (2009) \textit{Staphylococcus aureus} phage-encoded adhesins mediate attachment to sialylated sialic acid residues on platelet membrane gangliosides. Infect Immun 77: 3485–3490.

28. Que YA, Moreillon P (2011) Infective endocarditis. Nat Rev Cardiol 8: 322–336.

29. Grothegar JA, Ganesh VK, Smeds E, Liang X, Hook M, et al. (2009) Molecular characterization of the interaction of staphylococcal microbial surface components recognizing adhesive matrix molecules (MSCRAMMs). CIEA and Fbl with fibrinogen. J Biol Chem 284: 6280–6286.

30. Shannon O, Hock JH (2008) Extracellular fibrinogen binding protein, EfB, from \textit{Streptococcus agalactiae} binds to platelets and inhibits platelet aggregation. Thromb Haemost 97: 779–789.

31. Santoro J, Levison ME (1978) Rat model of experimental endocarditis. Infect Immun 23: 1035–1044.

32. Santoro J, Levison ME (1978) Rat model of experimental endocarditis. Infect Immun 23: 1035–1044.

33. Santoro J, Levison ME (1978) Rat model of experimental endocarditis. Infect Immun 23: 1035–1044.

34. Santoro J, Levison ME (1978) Rat model of experimental endocarditis. Infect Immun 23: 1035–1044.

35. Santoro J, Levison ME (1978) Rat model of experimental endocarditis. Infect Immun 23: 1035–1044.

36. Santoro J, Levison ME (1978) Rat model of experimental endocarditis. Infect Immun 23: 1035–1044.

37. Santoro J, Levison ME (1978) Rat model of experimental endocarditis. Infect Immun 23: 1035–1044.

38. Santoro J, Levison ME (1978) Rat model of experimental endocarditis. Infect Immun 23: 1035–1044.

39. Santoro J, Levison ME (1978) Rat model of experimental endocarditis. Infect Immun 23: 1035–1044.

40. Santoro J, Levison ME (1978) Rat model of experimental endocarditis. Infect Immun 23: 1035–1044.

41. Santoro J, Levison ME (1978) Rat model of experimental endocarditis. Infect Immun 23: 1035–1044.

42. Santoro J, Levison ME (1978) Rat model of experimental endocarditis. Infect Immun 23: 1035–1044.

43. Santoro J, Levison ME (1978) Rat model of experimental endocarditis. Infect Immun 23: 1035–1044.

44. Santoro J, Levison ME (1978) Rat model of experimental endocarditis. Infect Immun 23: 1035–1044.

45. Santoro J, Levison ME (1978) Rat model of experimental endocarditis. Infect Immun 23: 1035–1044.

46. Santoro J, Levison ME (1978) Rat model of experimental endocarditis. Infect Immun 23: 1035–1044.

47. Santoro J, Levison ME (1978) Rat model of experimental endocarditis. Infect Immun 23: 1035–1044.